Overview of KCNE4: A Potential Drug Target for Epilepsy, Heart Failure and Atrial Fibrillation

Target Name: KCNE4

NCBI ID: G23704

KCNE4

Other Name(s): Potassium voltage-gated channel Isk-related family member 4 | MINK-related peptide 3 | cardiac voltage-gated potassium channel accessory subunit 4 | Potassium voltage-gated channel subfamily E member 4 | potassium voltage-gated channel subfamily E regulatory subunit 4 | MIRP3 | Potassium channel beta subunit MiRP3 | Potassium voltage-gated channel subfamily E regulatory subunit 4 | KCNE4_HUMAN | minimum potassium ion channel-related peptide 3 | potassium voltage-gated channel, Isk-related family, member 4 | Minimum potassium ion channel-related peptide 3 | Potassium channel subunit beta MiRP3 | MinK-related peptide 3 | potassium channel, voltage gated subfamily E regulatory beta subunit 4 | potassium channel subunit beta MiRP3

Overview of KCNE4: A Potential Drug Target for Epilepsy, Heart Failure and Atrial Fibrillation

KCNE4, a member of the Isk-related family of voltage-gated potassium channels, has been identified as a potential drug target in various diseases, including epilepsy, heart failure, and atrial fibrillation. This article will provide an overview of KCNE4, its function in the body, potential drug targets, and current research in the field.

Function and Localization

KCNE4 is a member of the Isk-related family of voltage-gated potassium channels, which are responsible for regulating the movement of positively charged ions, specifically potassium, into and out of cells. These channels are found in various tissues and organs throughout the body, including the heart, brain, and kidneys.

KCNE4 is primarily localized to the cardiac and skeletal muscles. It is expressed in the cardiac muscle, including the atria, ventricles, and the atrioventricular (AV) node, and is also found in the skeletal muscles, including the diaphragm and muscle fibers.

Potential Drug Targets

KCNE4 has been identified as a potential drug target due to its involvement in various diseases, including epilepsy, heart failure, and atrial fibrillation.

Epilepsy

KCNE4 has been shown to play a role in the pathophysiology of epilepsy, particularly in the propagation of seizures. Studies have shown that modulation of KCNE4 activity can be an effective way to treat epilepsy and that inhibiting its function may be a potential new treatment strategy.

Heart Failure

KCNE4 has also been shown to be involved in the pathophysiology of heart failure, a condition in which the heart is unable to pump enough blood to meet the body's needs. Studies have shown that modulation of KCNE4 activity can be an effective way to treat heart failure and that activating its function may be a potential new treatment strategy.

Atrial Fibrillation

KCNE4 has also been shown to be involved in the pathophysiology of atrial fibrillation, a condition in which the heart's normal electrical activity is disrupted, leading to a rapid and irregular heartbeat. Studies have shown that modulation of KCNE4 activity can be an effective way to treat atrial fibrillation and that inhibiting its function may be a potential new treatment strategy.

Current Research

Current research is focused on the modulation of KCNE4 activity in order to understand its role in various diseases and to identify potential drug targets. This is done through a variety of techniques, including pharmacological and genetic modulation, as well as cell-based assays.

Pharmacological Modulation

One way to modulate KCNE4 activity is through the use of small molecules that can bind to its channels. Researchers have identified a number of potential small molecules that can modulate KCNE4 activity, including some that are currently being tested in clinical trials for the treatment of epilepsy and heart failure.

Genetic Modulation

Another way to modulate KCNE4 activity is through the use of genetic modification techniques, such as RNA interference or CRISPR/Cas9. Researchers have identified a number of potential genetic modifications that can affect KCNE4 expression and activity, and are using these techniques to study its role in various diseases.

Conclusion

KCNE4 is a member of the Isk-related family of voltage-gated potassium channels that is involved in the regulation of various physiological processes in the body. Its function is primarily localized to the cardiac and skeletal muscles, and it has been identified as a potential drug target due to its involvement in the pathophysiology of epilepsy, heart failure, and atrial fibrillation. Current research is focused on modulating KCNE4 activity through a variety of techniques, including pharmacological and genetic modulation, in order to understand its role in these diseases and to identify potential drug targets.

Protein Name: Potassium Voltage-gated Channel Subfamily E Regulatory Subunit 4

Functions: Ancillary protein that assembles as a beta subunit with a voltage-gated potassium channel complex of pore-forming alpha subunits. Modulates the gating kinetics and enhances stability of the channel complex. May associate with KCNQ1/KVLTQ1 and inhibit potassium current

The "KCNE4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNE4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets